SPRY
ARS Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.54
−3.42%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 2.15x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 28.10x
- Price / sales
- 3.01x
- Price / cash flow
- -1.79x
Enterprise value
- Enterprise value
- $379.3M
- EV / sales
- 3.24x
- EV / EBITDA
- -1.83x
- EV / EBIT
- -1.75x
- Market cap
- $351.5M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026